Sugar-coated zebrafish

In a single day, biotech company VASTox

Register for free to listen to this article
Listen with Speechify
0:00
5:00
OXFORD, U.K.—In a single day, biotech company VASTox made major moves to expand its capabilities, announcing the acquisition of Cambridge, UK-based DanioLabs and Reading, UK-based Dextra Laboratories. The deals see the company expand its pipeline with two clinical and two preclinical programs, as well as expanding it R&D capabilities in the areas of chemical genomics using zebrafish and sugar chemistry.
 
DanioLabs was acquired for £15 million in shares and cash, with VASTox retaining its research facility and maintaining its 37 personnel. Meanwhile, Dextra had a lower price tag of £1.5 million, also paid in shares, and as with the other deal, VASTox will retain the chemistry facility and all 17 employees.
 
"The acquisitions of DanioLabs and Dextra represent a transforming development for VASTox," said VASTox CEO Dr. Steve Lee. "Following these transactions, plus the earlier deal with MNL Pharma in December 2006, VASTox now has a broad drug discovery pipeline with programs in clinical and discovery phases of development targeting neuro-disorders, cancer, ophthalmology, infectious diseases and regenerative medicine."


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Drug Discovery News November 2024 Issue

Latest Issue  

• Volume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue